Jia Y, Liu M, Cao L, Zhao X, Wu J, Lu F, Li Y, He Y, Ren S, Ju Y, Wang Y, Li Z
Oncology Department, Hebei General Hospital, Shijiazhuang, Hebei, China.
Eur J Gynaecol Oncol. 2011;32(3):316-24.
The effects of recombinant human endostatin, Endostar, combined with concurrent chemo-radiotherapy (CCRT) on tumor growth, angiogenesis and lymphangiogenesis in a mouse xenograft model of cervical cancer was investigated.
HeLa cells were injected subcutaneously to establish mouse xenograft models and mice were treated with normal saline (control), CCRT with cisplatin (CDDP), Endostar, or a combination of Endostar and CCRT. Growth, metastasis, and angiogenesis of tumors was monitored.
Tumorogenic activity of tumor cells in the CCRT, Endostar and combination Endostar-CCRT treatment groups was markedly decreased compared with the activity in the NS group (p < 0.05). The most significant inhibition of tumor growth was observed in the Endostar with CCRT group. Lymph node metastases in the Endostar with CCRT group (12.5%) and Endostar alone group (25%) were lower compared to the CCRT group (42.8%) and NS group (66.7%; p < 0.05). Endostar was also found to inhibit tumor angiogenesis. Endostar induced apoptosis of HeLa cells in vivo, and inhibited expression of VEGF and HIF-1alpha in vivo and in vitro.
Endostar enhanced the anti-cancer effect of CCRT in a mouse xenograft model of cervical cancer. These findings thus provide a new strategy to treat cervical cancer.
研究重组人内皮抑素（恩度）联合同步放化疗（CCRT）对宫颈癌小鼠异种移植模型中肿瘤生长、血管生成和淋巴管生成的影响。
皮下注射人宫颈癌HeLa细胞建立小鼠异种移植模型，小鼠分别接受生理盐水（对照）、顺铂（CDDP）同步放化疗、恩度或恩度联合同步放化疗治疗。监测肿瘤的生长、转移和血管生成情况。
与生理盐水组相比，同步放化疗组、恩度组及恩度联合同步放化疗组肿瘤细胞的致瘤活性显著降低（p<0.05）。恩度联合同步放化疗组对肿瘤生长的抑制作用最为显著。恩度联合同步放化疗组（12.5%）和单纯恩度组（25%）的淋巴结转移率低于同步放化疗组（42.8%）和生理盐水组（66.7%；p<0.05）。还发现恩度可抑制肿瘤血管生成。恩度在体内可诱导HeLa细胞凋亡，并在体内和体外抑制VEGF和HIF-1α的表达。
在宫颈癌小鼠异种移植模型中，恩度增强了同步放化疗的抗癌效果。这些研究结果为宫颈癌的治疗提供了一种新策略。
